PMID: 1194717Dec 1, 1975Paper

Treatment of psoriasis with oral mycophenolic acid

The Journal of Investigative Dermatology
E L JonesP Frost

Abstract

Mycophenolic acid (MPA), an inhibitor of purine synthesis, was evaluated for its therapeutic and adverse effects in 29 patients with psoriasis. MPA was administered orally for at least 12 weeks, during which time the daily dose was increased from 1600 to 4800 mg depending on occurrence of adverse reactions. Complete clearing occurred in 1 of the patients, almost complete clearing in 14, definite improvement in 13, slight or doubtful improvement in 1. The full effect of MPA required a median time of 8 weeks (range 5-14). After discontinuing MPA, relapses began at a median time of 4 weeks (range 3-8). The severity of psoriasis was scored on a 0 to 108 scale using a newly devised system. The mean severity and range before treatment was 47 (21-88); after 12 weeks, 15 (0-50). Adjustment of dose on the basis of side effects resulted in a median daily dose of 3600 mg (range 2400-4800 mg; 30-96 mg/kg ideal weight). Characteristic dose-limiting side effects were soft or frequent bowel movements, diarrhea, nausea, and anorexia. One instance of reversible, dose-related leukopenia was identified.

Citations

Sep 1, 1977·The British Journal of Dermatology·E C GomezP Frost
Apr 16, 1998·The British Journal of Dermatology·M G HaufsT A Luger
Sep 25, 1998·The British Journal of Dermatology·C C GeilenC E Orfanos
May 4, 1999·The Journal of Clinical Investigation·J R AbramsS Kang
Aug 22, 2000·The British Journal of Dermatology·K NeuberA T Dieck
Oct 28, 2003·The Journal of Dermatological Treatment·Mark LebwohlSteven Feldman
Sep 4, 2004·Clinical Transplantation·Hans W Sollinger
Nov 1, 2007·Dermatologic Therapy·Jeffrey Zwerner, David Fiorentino
Apr 12, 2013·The Australasian Journal of Dermatology·Jane LiChristopher Baker
Sep 14, 2019·Cancers·Rand NaffoujeAtsuo T Sasaki
Mar 22, 2001·The British Journal of Dermatology·C C GeilenC E Orfanos
Dec 9, 2003·The Journal of Dermatological Treatment·V Liu, B T Mackool
Jan 6, 2015·The Australasian Journal of Dermatology·Sarah J Strathie Page, Clare P Tait
Feb 15, 2020·Nature Reviews. Rheumatology·Jasper C A Broen, Jacob M van Laar
Aug 22, 2000·The British Journal of Dermatology·S C DavisonL Fry
Apr 30, 2002·American Journal of Clinical Dermatology·Jennifer Cather, Alan Menter
Sep 5, 2001·The British Journal of Dermatology·M Grundmann-KollmannT M Zollner
Dec 5, 2002·Clinical and Experimental Dermatology·U Frieling, T A Luger
Jan 15, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·V SchleyerR-M Szeimies
Jun 23, 2009·Drugs·Anna L ChienCharles N Ellis
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Sharon E Jacob, Mari Paz Castanedo-Tardan
Oct 31, 2018·Journal of Veterinary Pharmacology and Therapeutics·Michael KlotsmanPadmaja Shivanand
Feb 3, 2005·Nature Reviews. Drug Discovery·Alice B Gottlieb
Aug 10, 1999·The Australasian Journal of Dermatology·D W Tong, B K Walder
Apr 5, 2005·Lupus·M Hartmann, A Enk
Apr 1, 1978·The British Journal of Dermatology·S SpatzC J McDonald
Nov 17, 2001·Journal of Chromatography. B, Biomedical Sciences and Applications·K WiwattanawongsaP C Smith
Jul 6, 2000·Immunopharmacology·T S Mele, P F Halloran
Jan 1, 1981·Pharmacology & Therapeutics·C J McDonald
Jun 1, 1982·Antimicrobial Agents and Chemotherapy·J D Berman, H K Webster
Jun 5, 2003·Clinics in Dermatology·Arash Akhavan, Donald Rudikoff
Jun 11, 1999·Journal of the American Society of Nephrology : JASN·J F GummertR E Morris
Jul 1, 1976·The Journal of Investigative Dermatology·G D Weinstein, J L McCullough
Jul 31, 2007·Lancet·Alan Menter, Christopher Em Griffiths
Sep 20, 2011·Dermatologic Clinics·Marina Eskin-SchwartzDaniel Mimouni
Apr 25, 2000·Journal of the American Academy of Dermatology·M Grundmann-KollmannR U Peter
Apr 25, 2000·Journal of the American Academy of Dermatology·C C Geilen, U Mrowietz
May 9, 2012·Immunology and Allergy Clinics of North America·Marina Eskin-SchwartzDaniel Mimouni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Related Papers

Journal of the American Academy of Dermatology
E C GomezP Frost
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Chen HaoLi Hongwei
© 2022 Meta ULC. All rights reserved